126 related articles for article (PubMed ID: 2820737)
1. Experience with bacillus Calmette-Guérin in patients with superficial bladder tumors. Value of monocyte activation in intravesical bacillus Calmette-Guérin therapy.
Nissenkorn I; Lavie G; Keisari Y; Leib Z; Vilcovsky E; Servadio C; Shachter H
Eur Urol; 1987; 13(4):246-50. PubMed ID: 2820737
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
3. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
5. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
6. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
9. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
11. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
12. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
[TBL] [Abstract][Full Text] [Related]
13. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
14. Bladder cancer immunotherapy.
Lamm DL; Thor DE; Stogdill VD; Radwin HM
J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
[TBL] [Abstract][Full Text] [Related]
15. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
16. [Intravesical bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder tumors. Ablative and prophylactic effects of intravesical BCG on papillary tumors].
Hagiwara M; Ohigashi T; Nakazono M; Asakura H; Tsukamoto T; Iigaya T; Yamamoto T; Shishido S; Hayashi A; Yamamoto H
Nihon Hinyokika Gakkai Zasshi; 1988 Mar; 79(3):521-6. PubMed ID: 3221605
[No Abstract] [Full Text] [Related]
17. Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guérin--a useful marker of response?
Schmidt AC; Bouic PJ; Heyns CF; De Kock ML
Br J Urol; 1993 Feb; 71(2):179-82. PubMed ID: 8461951
[TBL] [Abstract][Full Text] [Related]
18. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
[TBL] [Abstract][Full Text] [Related]
20. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
Loertzer H; Brake M; Horsch R; Keller H
Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]